Research Article
The Prognostic Value of Serum Apolipoprotein A-I Level and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Liver Metastasis
Table 1
The clinical characteristics of patients grouped according to ApoA-I level and NLR.
| | Variables | | | value | | | value |
| | N | 119 | 118 | | 119 | 118 | | | Age | | | 0.411 | | | 0.269 | | Sex | | | 0.713 | | | 0.520 | | (i) Male | 78 (65.546%) | 80 (67.797%) | | 77 (64.706%) | 81 (68.644%) | | | (ii) Female | 41 (34.454%) | 38 (32.203%) | | 42 (35.294%) | 37 (31.356%) | | | Liver metastases number | | | 0.359 | | | 0.155 | | (i) ≤2 | 29 (24.370%) | 35 (29.661%) | | 37 (31.092%) | 27 (22.881%) | | | (ii) >2 | 90 (75.630%) | 83 (70.339%) | | 82 (68.908%) | 91 (77.119%) | | | Type of liver metastases | | | 0.430 | | | 0.189 | | (i) Simultaneous | 92 (77.311%) | 86 (72.881%) | | 85 (71.429%) | 93 (78.814%) | | | (ii) Metachronous | 27 (22.689%) | 32 (27.119%) | | 34 (28.571%) | 25 (21.186%) | | | Tumor location | | | 0.852 | | | 0.169 | | (i) LCRC | 89 (74.790%) | 87 (73.729%) | | 93 (78.070%) | 83 (71.681%) | | | (ii) RCC | 30 (25.210%) | 31 (26.271%) | | 26 (21.930%) | 35 (28.319%) | | | Pathological type | | | 0.362 | | | 0.347 | | (i) Adenocarcinoma | 112 (94.118%) | 114 (96.610%) | | 115 (96.639%) | 111 (94.068%) | | | (ii) Nonadenocarcinoma | 7 (5.882%) | 4 (3.390%) | | 4 (3.361%) | 7 (5.932%) | | | Degree of tumor differentiation | | | 0.363 | | | 0.416 | | (i) Moderately | 88 (73.950%) | 94 (79.661%) | | 91 (76.470%) | 91 (77.119%) | | | (ii) Poorly | 22 (18.487%) | 14 (11.864%) | | 16 (13.445%) | 20 (16.949%) | | | (iii) Well | 9 (7.563%) | 10 (8.475%) | | 12 (10.084%) | 7 (5.932%) | | | cT classification | | | 0.846 | | | 0.558 | | (i) 1-3 | 58 (48.739%) | 59 (50.000%) | | 61 (51.261%) | 56 (47.458%) | | | (ii) 4 | 61 (51.261%) | 59 (50.000%) | | 58 (48.739%) | 62 (52.542%) | | | cN classification | | | 0.542 | | | 0.213 | | (i) 0-1 | 69 (57.983%) | 73 (61.864%) | | 76 (63.866%) | 66 (55.932%) | | | (ii) 2-3 | 50 (42.017%) | 45 (38.136%) | | 43 (36.134%) | 52 (44.068%) | | | KPS scores | | | <0.001 | | | 0.026 | | (i) ≥80 | 80 (67.227%) | 105 (88.983%) | | 100 (84.034%) | 85 (72.034%) | | | (ii) <80 | 39 (32.773%) | 13 (11.017%) | | 19 (15.966%) | 33 (27.966%) | | | Primary surgery | | | 0.009 | | | 0.007 | | (i) No | 57 (47.899%) | 37 (31.356%) | | 37 (31.092%) | 57 (48.305%) | | | (ii) Yes | 62 (52.101%) | 81 (68.644%) | | 82 (68.908%) | 61 (51.695%) | | | Chemotherapy | | | 0.076 | | | <0.001 | | (i) No | 44 (36.975%) | 31 (26.271%) | | 25 (21.008%) | 50 (42.373%) | | | (ii) Yes | 75 (63.025%) | 87 (73.729%) | | 94 (78.992%) | 68 (57.627%) | | | Targeted therapy | | | 0.688 | | | 0.688 | | (i) No | 86 (72.269%) | 88 (74.576%) | | 86 (72.269%) | 88 (74.576%) | | | (ii) Yes | 33 (27.731%) | 30 (25.424%) | | 33 (27.731%) | 30 (25.424%) | | | Topical treatment | | | 0.421 | | | 0.098 | | (i) No | 94 (78.992%) | 88 (74.576%) | | 86 (72.269%) | 96 (81.356%) | | | (ii) Yes | 25 (21.008%) | 30 (25.424%) | | 33 (27.731%) | 22 (18.644%) | | | Metastasis surgery | | | 0.691 | | | 0.068 | | (i) No | 103 (86.555%) | 100 (84.746%) | | 97 (81.513%) | 106 (89.831%) | | | (ii) Yes | 16 (13.445%) | 18 (15.254%) | | 22 (18.487%) | 12 (10.169%) | |
|
|
considered as statistically significant. |
